BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Apr 12, 2010
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 4/9 cls
Actelion Ltd. (SIX:ATLN) UBS Martin Wales Upgrade Buy (from neutral) 3% CHF49.85
Wales said he thinks the shares have been oversold since Tracleer bosentan failed in the Phase III BUILD-3 trial to treat idiopathic pulmonary fibrosis (IPF) (see BioCentury, March 8). However, Wales lowered his target to CHF55 from CHF58 to reflect a bearish view on the company's pipeline and weaker sales for Ventavis iloprost, an inhaled prostacyclin analog for pulmonary arterial hypertension (PAH), partnered with Bayer AG (Xetra:BAY).
Celgene Corp. (NASDAQ:CELG) Baird Christopher Raymond Price target Market outperform 0% $61.89
Jefferies Thomas Wei Downgrade Hold (from buy)
Raymond raised his target to $70 from $65 after Celgene held its R&D day. He was "impressed" by the company's "increasingly diverse...

Read the full 952 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >